311 related articles for article (PubMed ID: 15518283)
1. [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(5):36-8. PubMed ID: 15518283
[TBL] [Abstract][Full Text] [Related]
2. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
6. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
7. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
8. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
[TBL] [Abstract][Full Text] [Related]
9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
10. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
11. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
13. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
Plaisant N; Quenet F; Fabbro M; Gourgou S; Gutowski M; Saint-Aubert B; Rouanet P
Gynecol Obstet Fertil; 2004 May; 32(5):391-7. PubMed ID: 15177208
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
15. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum.
Look M; Chang D; Sugarbaker PH
Int J Gynecol Cancer; 2004; 14(1):35-41. PubMed ID: 14764027
[TBL] [Abstract][Full Text] [Related]
17. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
20. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
Bloss JD; Liao SY; Buller RE; Manetta A; Berman ML; McMeekin S; Bloss LP; DiSaia PJ
Gynecol Oncol; 1993 Sep; 50(3):347-51. PubMed ID: 8406199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]